A Transforming Growth Factorβ1 Signal Peptide Variant Increases Secretion in Vitro and Is Associated with Increased Incidence of Invasive Breast Cancer

There is evidence that transforming growth factor (TGF)beta acts as a suppressor of tumor initiation but also as a promoter of tumor progression when the antiproliferative effect of the TGFbeta signaling pathway has been overridden by other oncogenic mutations. Several somatic mutations that disrupt the TGFbeta-SMAD signaling pathway have been reported in human breast tumors. We have examined the association between single nucleotide polymorphisms (SNPs) in the TGFbeta1 gene and the incidence of invasive breast cancer in three case-control series, with a maximum of 3987 patients and 3867 controls, median age approximately 50 years, and range 22-92 years. The promoter SNP, C-509T, and the T +29C signal-peptide SNP (encoding Leu10Pro) are in strong linkage disequilibrium. They are both significantly associated with increased incidence of invasive breast cancer in a recessive manner [odds ratios: (TT versus C-carrier), 1.25; 95% confidence intervals 1.06-1.48; P = 0.009 and (ProPro versus Leu-carrier), 1.21; 95% confidence intervals 1.05-1.37; P = 0.01]. The G-800A SNP was not significantly associated with incidence of breast cancer. The C-509T SNP is not contained within a known consensus sequence for a promoter regulatory element and therefore unlikely to affect TGFbeta1 expression, whereas the Leu10Pro signal peptide substitution potentially affects TGFbeta1 secretion. Transfections of HeLa cells with constructs encoding either the Pro or Leu forms of TGFbeta1 and driven by the cytomegalovirus promoter indicate that the signal peptide with Pro at residue 10 causes a 2.8-fold increase in secretion compared with the Leu form. These data indicate that the allele encoding Pro10 is associated with increased rates of TGFbeta1 secretion and with increased incidence of invasive breast cancer for the population samples described. It is estimated that 3% of all breast cancer cases may be attributable to Pro10 homozygosity.

[1]  J. Chang-Claude,et al.  Breastfeeding and breast cancer risk by age 50 among women in Germany , 2000, Cancer Causes & Control.

[2]  R. Dickson,et al.  Growth Factors, Apoptosis, and Survival of Mammary Epithelial Cells , 1999, Journal of Mammary Gland Biology and Neoplasia.

[3]  S. Sato,et al.  Transforming growth factor β1 gene polymorphism in rheumatoid arthritis , 2002, Annals of the rheumatic diseases.

[4]  R. Madhok,et al.  Analysis of transforming growth factor β1 gene polymorphisms in patients with systemic sclerosis , 2002, Annals of the rheumatic diseases.

[5]  A. Balmain,et al.  Metastasis is driven by sequential elevation of H-ras and Smad2 levels , 2002, Nature Cell Biology.

[6]  F. Ando,et al.  Association of a polymorphism of the transforming growth factor-β1 gene with blood pressure in Japanese individuals , 2002, Journal of Human Genetics.

[7]  M. Goumans,et al.  Balancing the activation state of the endothelium via two distinct TGF‐β type I receptors , 2002, The EMBO journal.

[8]  A. Gressner,et al.  Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[9]  J. Downward,et al.  Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis , 2002, The Journal of Cell Biology.

[10]  David L Rimm,et al.  Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. , 2002, Cancer research.

[11]  N E Day,et al.  A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.

[12]  J. Downward,et al.  Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. , 2002, The Journal of cell biology.

[13]  I. Adcock,et al.  TGFβ1 allele association with asthma severity , 2001, Human Genetics.

[14]  C. Bouchard,et al.  TGF-β1 gene-race interactions for resting and exercise blood pressure in the HERITAGE family study , 2001 .

[15]  W. Weimar,et al.  TGF-β1 gene polymorphisms in patients with end-stage heart failure , 2001 .

[16]  N E Day,et al.  Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population‐based study , 2001, Genetic epidemiology.

[17]  E. Ziv,et al.  Association between the T29-->C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. , 2001, JAMA.

[18]  D. Kang,et al.  Polymorphic catechol-O-methyltransferase gene and breast cancer risk. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  W. Weimar,et al.  THE TRANSFORMING GROWTH FACTOR-&bgr;1 CODON 10 GENE POLYMORPHISM AND ACCELERATED GRAFT VASCULAR DISEASE AFTER CLINICAL HEART TRANSPLANTATION , 2001, Transplantation.

[20]  A. Schulze,et al.  Analysis of the transcriptional program induced by Raf in epithelial cells , 2001, Nature Genetics.

[21]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[22]  W. Weimar,et al.  TGF-beta1 gene polymorphisms in patients with end-stage heart failure. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  O. Viklicky,et al.  TGF-beta I gene polymorphism in heart transplant recipients--effect on renal function. , 2001, Annals of transplantation.

[24]  R. Hesketh,et al.  Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer. , 2001, Cancer research.

[25]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[26]  I. Adcock,et al.  TGFbeta1 allele association with asthma severity. , 2001, Human genetics.

[27]  C. Bouchard,et al.  TGF-beta(1) gene-race interactions for resting and exercise blood pressure in the HERITAGE Family Study. , 2001, Journal of applied physiology.

[28]  A. Schulze,et al.  Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. , 2000, Genes & development.

[29]  Yoshiji Yamada,et al.  Association of a Leu10→Pro polymorphism of the transforming growth factor-β1 with genetic susceptibility to osteoporosis and spinal osteoarthritis , 2000, Mechanisms of Ageing and Development.

[30]  M. Yokota,et al.  Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. , 2000, Circulation.

[31]  L. Wakefield,et al.  Transforming growth factor-β and breast cancer: Lessons learned from genetically altered mouse models , 2000, Breast Cancer Research.

[32]  S. Markowitz TGF-beta receptors and DNA repair genes, coupled targets in a pathway of human colon carcinogenesis. , 2000, Biochimica et biophysica acta.

[33]  Anglian Breast Cancer Study Group Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000 .

[34]  H. Friess,et al.  The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer , 1999, Oncogene.

[35]  N. Day,et al.  EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. , 1999, British journal of cancer.

[36]  M. Rothmund,et al.  Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors , 1999, Oncogene.

[37]  K. Kinzler,et al.  Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. , 1999, Cancer research.

[38]  T. Spector,et al.  Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.

[39]  H. Friess,et al.  The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. , 1999, Oncogene.

[40]  J. Gunn,et al.  Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. , 1998, Clinical science.

[41]  J. Gunn,et al.  Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. , 1998, Clinical science.

[42]  M. Reiss,et al.  Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. , 1998, Cancer research.

[43]  M. Reiss,et al.  Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. , 1998, Cancer research.

[44]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[45]  N. Day,et al.  Family history and the risk of breast cancer: A systematic review and meta‐analysis , 1997, International journal of cancer.

[46]  D. Arveiler,et al.  Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. , 1996, Hypertension.

[47]  J. Bartlett,et al.  Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. , 1996, British Journal of Cancer.

[48]  Julian Peto,et al.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies , 1996, The Lancet.

[49]  M. Sporn,et al.  Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. , 1992, Cancer research.

[50]  A G Babiker,et al.  Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. , 1991, Statistics in medicine.